DOSAGE INDEX / SINGLE
Cagrilintide
Research, reported schedules and supply planning.
Explore cagrilintide biology, monotherapy weight-loss findings, newer diabetes research, tolerability and the distinction from CagriSema combination results.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 0.6–4.5 mg per week
- Frequency
- Once weekly
- Cycle / observation period
- 12–16 weeks or longer in the source
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Acidic diluent / GA water: under formulation review. Acetic-acid concentration, glycerin content, peptide salt form and intended laboratory use must be specified before compatibility can be assessed. No acidic diluent has been assigned to this product or blend.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2025 study compared ordinary mice with mice lacking RAMP1 and RAMP3, proteins involved in amylin receptor complexes. In high-fat-fed male mice, cagrilintide lowered weight in the ordinary-mouse group; the effect was impaired in the knockout group. The treatment period was three weeks. [1]
- In REIMAGINE 2, the cagrilintide-alone arm included 152 participants. At 68 weeks, the efficacy analysis showed HbA1c change of -0.80 percentage points versus +0.09 with placebo, and weight change of -8.4% versus -1.5%. These were secondary comparisons in a trial whose primary question concerned the combination against semaglutide. [2]
- In the monotherapy phase 2 trial, gastrointestinal adverse events occurred in 41% to 63% of cagrilintide participants across the dose groups, versus 32% with placebo. Nausea occurred in 20% to 47% versus 18%. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 40 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original mouse study
- Original REIMAGINE 2 publication
- Original safety findings
- Bachem: peptide solubility and handling guidance (laboratory methods)
- Int J Mol Sci (2024)Further reading · Listed in reference bibliography.
- PMC (2022)Further reading · Listed in reference bibliography.
- The Lancet (2021)Further reading · Listed in reference bibliography.
- N Engl J Med (2025)Further reading · Listed in reference bibliography.
- The Lancet (2021)Further reading · Listed in reference bibliography.
- J Med Chem (2021)Further reading · Listed in reference bibliography.
- Brain Res Rev (2005)Further reading · Listed in reference bibliography.
- PMC (2006)Further reading · Listed in reference bibliography.
- PMC (2016)Further reading · Listed in reference bibliography.
- PMC (2024)Further reading · Listed in reference bibliography.
- N Engl J Med (2025)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDC (PDF)General guidance · Listed in reference bibliography.
- PMC (2019)Further reading · Listed in reference bibliography.
- American College of Cardiology (2025)Further reading · Listed in reference bibliography.
- The Lancet (2023)Further reading · Listed in reference bibliography.
- PMC (2024)Further reading · Listed in reference bibliography.
- EudraCT 2018-001945-14 Phase 2 cagrilintide trial results with exact randomized arms, escalation schedules, formulation, and 26-week durationFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.